- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
argenx SE BDR (A1RG34)
argenx SE BDR stock price live, this page displays BVMF A1RG34 stock exchange data. View the A1RG34 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the argenx SE BDR real time stock price chart below.
What Is the argenx SE BDR Stock Price Today?
The argenx SE BDR stock price today is 194.94.
What Is the Stock Symbol for argenx SE BDR?
The stock symbol for argenx SE BDR is "A1RG34."
What Stock Exchange Does argenx SE BDR Trade On?
argenx SE BDR is listed and trades on the B3 stock exchange.
Is argenx SE BDR a Good Stock to Buy?
Determining whether argenx SE BDR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the A1RG34 quote. (ISIN: BRA1RGBDR004)
What Is the argenx SE BDR Stock Price Today?
The argenx SE BDR stock price today is 194.94.
What Is the Stock Symbol for argenx SE BDR?
The stock symbol for argenx SE BDR is "A1RG34."
What Stock Exchange Does argenx SE BDR Trade On?
argenx SE BDR is listed and trades on the B3 stock exchange.
Is argenx SE BDR a Good Stock to Buy?
Determining whether argenx SE BDR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the A1RG34 quote. (ISIN: BRA1RGBDR004)
B3
Currency in BRL
194.94
+32.81(+20.24%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
194.94
196.08
52 wk Range
143.22
213.15
A1RG34 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
194.94196.08
52 wk Range
143.22213.15
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
A1RG34 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high earnings multiple
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Earnings
Latest Release
Oct 22, 2026
EPS / Forecast
7.80 / --
Revenue / Forecast
1.75B / --
Compare A1RG34 to Peers and Sector
Metrics to compare | A1RG34 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipA1RG34PeersSector | |
|---|---|---|---|---|
P/E Ratio | 30.0x | 30.6x | −0.3x | |
PEG Ratio | 1.25 | 0.00 | 0.00 | |
Price/Book | 6.7x | 3.8x | 2.6x | |
Price / LTM Sales | 9.5x | 4.0x | 2.8x | |
Upside (Analyst Target) | - | 39.3% | 66.6% | |
Fair Value Upside | Unlock | 6.4% | 9.1% | Unlock |
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the argenx SE BDR (A1RG34) Stock Price Today?
The argenx SE BDR stock price today is 194.94 BRL.
What Stock Exchange Does argenx SE BDR Trade On?
argenx SE BDR is listed and trades on the B3 Stock Exchange.
What Is the Stock Symbol for argenx SE BDR?
The stock symbol for argenx SE BDR is "A1RG34."
What Is the argenx SE BDR Market Cap?
As of today, argenx SE BDR market cap is 306.21B BRL.
What Is argenx SE BDR's Earnings Per Share (TTM)?
The argenx SE BDR EPS (TTM) is 156.06.
From a Technical Analysis Perspective, Is A1RG34 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has argenx SE BDR Stock Split?
argenx SE BDR has split 0 times.
How Many Employees Does argenx SE BDR Have?
argenx SE BDR has 1863 employees.
What is the current trading status of argenx SE BDR (A1RG34)?
As of Oct 31, 2026, argenx SE BDR (A1RG34) is trading at a price of 194.94 BRL, with a previous close of 194.94 BRL. The stock has fluctuated within a day range of 194.94 BRL to 196.08 BRL, while its 52-week range spans from 143.22 BRL to 213.15 BRL.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.